Suppr超能文献

髓母细胞瘤——生物学与微环境:综述

Medulloblastoma-biology and microenvironment: a review.

作者信息

Byrd Tiara, Grossman Robert G, Ahmed Nabil

机构信息

Department of Pediatrics, Baylor College of Medicine, Center for Cell and Gene Therapy, Houston, Texas 77030, USA.

出版信息

Pediatr Hematol Oncol. 2012 Sep;29(6):495-506. doi: 10.3109/08880018.2012.698372. Epub 2012 Jun 28.

Abstract

Medulloblastoma (MB) is a cancer of the cerebellum and the most common primary pediatric malignancy of the central nervous system. Classified as a primitive neural ectoderm tumor; it is thought to arise from granule cell precursors in the cerebellum. The standard of care consists of surgery, chemotherapy and age-dependent radiation therapy. Despite aggressive multimodality therapy; approximately 30% of MB patients remain incurable. Moreover, for long-term survivors, the treatment related sequelae are often debilitating. Side effects include cerebellar mutism, sterility, neurocognitive deficits, and a substantial risk of developing secondary cancers. In a quest for more effective and targeted therapies, scientists have begun to investigate the biological events that not only initiate but also sustain the malignant phenotype in MB. Of particular interest is, the role of the tumor microenvironment in tumor pathogenesis. This review seeks to highlight several key processes observed in cancer biology, particularly the involvement of the tumor microenvironment, with relevant examples from MB.

摘要

髓母细胞瘤(MB)是一种小脑癌症,也是中枢神经系统最常见的原发性儿科恶性肿瘤。它被归类为原始神经外胚层肿瘤,被认为起源于小脑的颗粒细胞前体。治疗标准包括手术、化疗和根据年龄进行的放射治疗。尽管采用了积极的多模态治疗,但仍有大约30%的MB患者无法治愈。此外,对于长期存活者来说,与治疗相关的后遗症往往使人虚弱。副作用包括小脑缄默症、不育、神经认知缺陷以及发生继发性癌症的重大风险。为了寻求更有效和有针对性的治疗方法,科学家们已经开始研究不仅启动而且维持MB恶性表型的生物学事件。特别令人感兴趣的是肿瘤微环境在肿瘤发病机制中的作用。本综述旨在强调癌症生物学中观察到的几个关键过程,特别是肿瘤微环境的参与,并列举MB的相关实例。

相似文献

1
Medulloblastoma-biology and microenvironment: a review.
Pediatr Hematol Oncol. 2012 Sep;29(6):495-506. doi: 10.3109/08880018.2012.698372. Epub 2012 Jun 28.
2
Childhood medulloblastoma: progress and future challenges.
Brain Dev. 1999 Mar;21(2):75-81. doi: 10.1016/s0387-7604(98)00085-0.
3
Medulloblastoma: presentation, diagnosis and management.
Oncology (Williston Park). 1988 Sep;2(9):35-45, 48-9.
4
Potential use of CXCL12/CXCR4 and sonic hedgehog pathways as therapeutic targets in medulloblastoma.
Acta Oncol. 2018 Sep;57(9):1134-1142. doi: 10.1080/0284186X.2018.1473635. Epub 2018 May 17.
5
Medulloblastoma: From Molecular Subgroups to Molecular Targeted Therapies.
Annu Rev Neurosci. 2018 Jul 8;41:207-232. doi: 10.1146/annurev-neuro-070815-013838. Epub 2018 Apr 11.
6
Epigenetic-Based Therapy-A Prospective Chance for Medulloblastoma Patients' Recovery.
Int J Mol Sci. 2021 May 6;22(9):4925. doi: 10.3390/ijms22094925.
7
SnapShot: Medulloblastoma.
Cancer Cell. 2014 Dec 8;26(6):940-940.e1. doi: 10.1016/j.ccell.2014.11.015.
8
Review of the prognostic factors in medulloblastoma of children and adults.
Crit Rev Oncol Hematol. 2004 May;50(2):121-8. doi: 10.1016/j.critrevonc.2003.08.005.
9
Clinicopathological features of medulloblastoma: an overview with an emphasis on molecular biology.
Clin Neuropathol. 2007 May-Jun;26(3):93-110. doi: 10.5414/npp26093.
10
Medulloblastoma in childhood: new biological advances.
Lancet Neurol. 2007 Dec;6(12):1073-85. doi: 10.1016/S1474-4422(07)70289-2.

引用本文的文献

1
Immune cell landscape and immunotherapy of medulloblastoma.
Pediatr Investig. 2021 Jun 21;5(4):299-309. doi: 10.1002/ped4.12261. eCollection 2021 Dec.
2
Decoding the Roles of Astrocytes and Hedgehog Signaling in Medulloblastoma.
Curr Oncol. 2021 Aug 11;28(4):3058-3070. doi: 10.3390/curroncol28040267.
4
Evidence of Tumour Microenvironment and Stromal Cellular Components in Retinoblastoma.
Ocul Oncol Pathol. 2019 Feb;5(2):85-93. doi: 10.1159/000488709. Epub 2018 Jul 17.
5
Cellular immunotherapy for pediatric solid tumors.
Cytotherapy. 2015 Jan;17(1):3-17. doi: 10.1016/j.jcyt.2014.05.019. Epub 2014 Jul 28.
6
Adoptive cell therapies for glioblastoma.
Front Oncol. 2013 Nov 11;3:275. doi: 10.3389/fonc.2013.00275. eCollection 2013.
7
G-quadruplexes as potential therapeutic targets for embryonal tumors.
Molecules. 2013 Oct 10;18(10):12500-37. doi: 10.3390/molecules181012500.

本文引用的文献

2
Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
Acta Neuropathol. 2012 Apr;123(4):515-27. doi: 10.1007/s00401-011-0918-8. Epub 2011 Dec 9.
4
MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma.
Acta Neuropathol. 2012 Apr;123(4):501-13. doi: 10.1007/s00401-011-0923-y. Epub 2011 Dec 3.
5
Tumor microenvironment: becoming sick of Myc.
Cell Mol Life Sci. 2012 Mar;69(6):931-4. doi: 10.1007/s00018-011-0860-x. Epub 2011 Oct 28.
6
The tumor microenvironment.
Surg Oncol. 2012 Sep;21(3):172-7. doi: 10.1016/j.suronc.2011.09.001. Epub 2011 Oct 1.
7
Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target.
J Clin Invest. 2011 Oct;121(10):4043-55. doi: 10.1172/JCI57147. Epub 2011 Sep 26.
8
Leukocyte composition of human breast cancer.
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2796-801. doi: 10.1073/pnas.1104303108. Epub 2011 Aug 8.
9
Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells.
Cancer Res. 2011 Aug 15;71(16):5455-66. doi: 10.1158/0008-5472.CAN-11-1687. Epub 2011 Jun 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验